Aavant Research vs Paradigm Peptide
Independent side-by-side comparison across the 3 peptides both vendors sell. Composite scores, lab quality, and verified pricing.
Aavant Research
A grades on Tirzepatide (9 tests, avg 8.7) and Semaglutide (11 tests). Tighter score consistency than top peers.
Aavant Research full review →Paradigm Peptide
Top Retatrutide vendor by score (9.0 across 14 tests). Strong on metabolic peptides.
Paradigm Peptide full review →Side-by-side breakdown
| PEPTIDE | AAVANT RESEARCH | PARADIGM PEPTIDE | WINNER |
|---|---|---|---|
| Tirzepatide |
8.7
B+ (9 tests)
|
8.4
B+ (14 tests)
|
Aavant Research |
| Retatrutide |
8.5
B+ (8 tests)
|
7.0
B (14 tests)
|
Aavant Research |
| Semaglutide |
8.5
B+ (11 tests)
|
—(not sold)
|
Aavant Research only |
| Ipamorelin |
8.2
B+ (5 tests)
|
9.0
A (6 tests)
|
Paradigm Peptide |
Which to choose
Across the 3 peptides both vendors sell, Aavant Research scores higher on 1, Paradigm Peptide scores higher on 1, and 1 are within 0.3 points (effectively tied). Aavant Research additionally sells Semaglutide; Paradigm Peptide does not.
Choose Aavant Research for: Retatrutide.
Choose Paradigm Peptide for: Ipamorelin.
Either works for Tirzepatide — composite scores are within 0.3 points.
Composite scores reflect lab quality, sentiment, COA transparency, reliability, and price. How we score.
Full profiles: Aavant Research review · Paradigm Peptide review